Bachem: CDMO Approaches to Pharma Supply Chain Challenges
In today's volatile global landscape, pharmaceutical supply chains face unprecedented challenges. From geopolitical tensions to natural disasters, disruptions have become increasingly common, threatening the delivery of life-saving medications worldwide.
The industry has weathered numerous global crises since the turn of the millennium, with the 2008 financial crisis, COVID-19 pandemic and the ongoing conflict in Ukraine exposing critical vulnerabilities in supply chain operations.
"Pharmaceutical supply chains are becoming increasingly vulnerable to a range of disruptions," explains Pascal Degen, Vice President of Global Supply Chain Management at Bachem. "The unpredictability of the modern world demands innovative strategies for maintaining stability in the face of disruption."
The impact of these disruptions is evident in stark statistics. Between late 2020 and early 2022, 255 clinical trials were initiated or completed in Ukraine. Following the outbreak of conflict, this number plummeted to just 33 from mid-2022 to mid-2023—an astonishing 87% reduction that underscores how regional instability can reverberate throughout global pharmaceutical operations.
Complex Challenges for CDMOs
Clearly, pharmaceutical manufacturing involves managing extensive, intricate supply chains.
Contract Development and Manufacturing Organisations (CDMOs) – tasked with ensuring compliance with regulations, operational efficiency and consistent product quality – face significant hurdles in maintaining smooth operations.
"CDMOs play a critical role in navigating challenges by ensuring the consistent production and delivery of life-saving medications," Pascal continues. "There is a pressing need for CDMOs to address supply chain challenges in a volatile, uncertain, complex and ambiguous (VUCA) environment."
The aforementioned challenges are multifaceted and include:
- Navigating varying international regulatory requirements across different markets
- Reducing overdependence on specific geographic regions for materials and manufacturing
- Overcoming the limitations of traditional batch manufacturing methods
The COVID-19 pandemic highlighted these vulnerabilities in devastating fashion. In 2020, the US alone experienced 143 shortages of different anaesthesia medications—a sobering reminder of what happens when supply chains falter.
The four pillars of supply chain resilience
According to Pascal, a robust framework for resilience must be built on four interconnected pillars:
Visibility
"Real-time supply chain monitoring ensures early detection of potential disruptions," Pascal states. "Tracking the flow of materials and production processes allows for swift corrective measures, minimising downstream impacts."
This visibility enables proactive management rather than reactive crisis responses, allowing supply chain leaders to anticipate problems before they cascade through the system.
Flexibility
Adaptability is crucial in an unpredictable environment.
"Adaptive strategies, including sourcing materials from a more diverse pool of suppliers and scalable manufacturing processes, enable CDMOs to respond to changing conditions effectively," says Pascal. "This flexibility reduces dependence on single-source suppliers and mitigates bottlenecks."
Flexible manufacturing processes that can easily pivot in response to material shortages or demand fluctuations provide a crucial competitive advantage.
Collaboration
No organisation can build resilience in isolation.
"Coordinated efforts among suppliers, manufacturers and logistics providers equip the entire supply chain with the ability to manage disruptions more effectively," Pascal emphasises. "Strong partnerships build mutual trust and a shared commitment to maintaining resilience."
These collaborative relationships create networks that can collectively absorb shocks and distribute risks more effectively than individual entities operating independently.
Control and transparency
The final pillar focuses on governance and communication.
"Clear communication, robust data management and adherence to regulatory requirements also build trust across the supply chain," explains Pascal. "Transparency in operations ensures alignment with stakeholders and mitigates risks."
Technology as an enabler of resilience
Innovation is transforming how pharmaceutical supply chains operate, offering new tools to enhance resilience.
"Innovative technologies are playing a pivotal role in reinforcing pharmaceutical supply chains," notes Pascal.
"Tools such as predictive analytics and blockchain analytics are helping to improve traceability, streamline operations and improve decision-making."
While traditional manufacturing methods remain dominant, emerging technologies are gradually reshaping the industry. Continuous purification processes, for instance, offer greater efficiency and scalability compared to batch manufacturing, potentially reducing vulnerabilities.
Future-proofing pharmaceutical supply chains
Looking ahead, Pascal outlines several key strategies for pharmaceutical companies navigating an increasingly unpredictable world.
"The pharmaceutical industry must adapt to a world where disruption is the norm," he adds.
This adaptation requires:
- Diversifying supply chains: Reducing reliance on specific regions or suppliers to mitigate risks
- Strengthening partnerships: Building robust relationships with stakeholders to promote more collaborative relationships
- Investing in technological innovation: Leveraging new technology to improve operational efficiency and resilience
- Improving agility: Developing flexible systems capable of responding to sudden changes in demand or supply conditions
Leading the charge for resilience
As disruptions become more frequent and severe, the pharmaceutical industry—particularly CDMOs—must prioritise supply chain resilience.
"As the pharmaceutical sector faces unprecedented challenges, the resilience of supply chains is paramount to ensuring the delivery of critical medications and patient safety," Pascal concludes.
"CDMOs must lead the charge by adopting comprehensive, forward-thinking strategies that address the complexities of a globalised industry."
By embracing the four pillars of visibility, flexibility, collaboration and transparency, organisations like Bachem are working to ensure that pharmaceutical supply chains can withstand whatever challenges the future holds—ultimately safeguarding patient wellbeing worldwide.
Explore the latest edition of Supply Chain Digital and be part of the conversation at our global conference series, Procurement & Supply Chain LIVE.
Discover all our upcoming events and secure your tickets today.
Supply Chain Digital is a BizClik brand.